Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 2/20 | 0.33 |
| ▸ | F7 | P08709 | 2/20 | 0.33 |
| ▸ | F3 | P13726 | 2/20 | 0.33 |
| ▸ | NQO2 | P16083 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17469624 | 0.77 | KIT (0.44) | KITFLT3NTRK3F2F7 | |
| SCHEMBL17469844 | 0.68 | FLT3 (0.42) | KITFLT3NTRK3F7F3 | |
| SCHEMBL19006220 | 0.68 | MERTK (0.35) | KITFLT3NTRK3F2F7 | |
| SCHEMBL17469804 | 0.67 | KDM1A (0.48) | FLT3 | |
| SCHEMBL17469733 | 0.67 | KDM1A (0.48) | FLT3 | |
| SCHEMBL17469647 | 0.67 | KIT (0.70) | KITFLT3NTRK3F2NQO2 | |
| SCHEMBL17469845 | 0.63 | PRSS1 (0.42) | F2F7F3 | |
| SCHEMBL17469622 | 0.62 | KIT (0.44) | KITFLT3NTRK3NQO2 | |
| SCHEMBL17469626 | 0.60 | FLT3 (0.47) | KITFLT3NTRK3F2F7 | |
| SCHEMBL17469638 | 0.60 | KIT (0.57) | KITFLT3NTRK3NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190209548-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | UNIVERSITY OF MARYLAND, BALTIMORE | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209548-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | MCL1, DPYD, TOP2B | KIT 2616/4885FLT3 2354/4885NTRK3 4453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.